CBG-002 is under clinical development by Carbiogene Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CBG-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBG-002 is under development for the treatment of relapsed/refractory multiple myeloma and unspecified indication. It is administered by intravenous route. The therapeutic candidate is a retroviral vector-transduced autologous T cells to express anti-BCMA CAR. it is being developed based on chimeric antigen receptor T cell therapy technology. It is administered through intravenous route.
For a complete picture of CBG-002’s drug-specific PTSR and LoA scores, buy the report here.